Using machine learning to identify patients with cancer that would benefit from immunotherapy
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
42
Respiratory Tract Diseases: News and Research on Carcinoma, Non-Small-Cell Lung
MeSH tree: C08.785.520.100.220.500
Combination therapy can delay resistance of lung cancer cells
A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...
Apr 16, 2024
0
47
Looking at the environment around tumors could help predict how cancer spreads
Examining the immune cells in the environment around a tumor could help to predict how a person's cancer might progress and respond to treatment, according to new research led by UCL and the Francis Crick Institute.
Apr 10, 2024
0
38
Genetically engineered dendritic cells enhance the power of immunotherapy against lung cancer
A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests that injecting engineered dendritic cells directly into cancerous lung tumors can help promote a stronger immune response, causing more ...
Mar 26, 2024
0
78
Q&A: Stem-immunity hubs associated with response to immunotherapy
Jonathan Chen, MD, Ph.D., an investigator in the Department of Pathology at Massachusetts General Hospital, and Nir Hacohen, Ph.D., director of the Center of Cancer Immunology at Massachusetts General Hospital, are co-authors ...
Mar 19, 2024
0
42
PD-L1 expression guidance on sintilimab vs. pembrolizumab with/without chemotherapy in untreated patients
A study published in the journal Science Bulletin was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Chinese Thoracic Oncology Group (CTONG)).
Mar 5, 2024
0
28
Genetic signature may predict response to immunotherapy for non-small cell lung cancer
A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results, ...
Feb 23, 2024
0
51
Clinical trial shows durvalumab plus ceralasertib boosted immune response in lung cancer patients
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study ...
Feb 13, 2024
0
50
Lazarus effect in a patient treated with osimertinib for non-small cell lung cancer with leptomeningeal disease
A new case report titled "Lazarus effect in a patient initially empirically treated with osimertinib for EGFR L858R mutant non-small cell lung cancer with leptomeningeal disease: a case report" has been published in Oncotarget.
Jan 24, 2024
0
49
Combination treatment improves lung cancer outcomes, finds study
A new study has found that patients with non-small cell lung cancer (NSCLC) treated with a combination of low-dose radiation and immunotherapy had higher progression-free survival compared to patients who received immunotherapy ...
Jan 16, 2024
0
46
